Deputy Chief Physician, a high-level talent in other categories in Hainan Province. In 2009, he obtained a masters degree in oncology from China Medical University and joined the Department of Medical Oncology at the Fourth Affiliated Hospital of China Medical University after graduation, during which he facilitated the clinical introduction of various new anti-tumor drugs. Since 2017, he has been employed at Hainan Cancer Hospital, specializing in the medical treatment of common malignant tumors such as breast cancer, lung cancer, gastric cancer, colorectal cancer, esophageal cancer, liver cancer, head and neck malignant tumors, and pleural mesothelioma through chemotherapy, targeted therapy, immunotherapy, and endocrine therapy. He has particularly in-depth research on anti-tumor treatment for elderly patients with malignant tumors. Additionally, he is practicing at Chengmei Hospital in Hainan Province and has pioneered the clinical application of immunotherapy, immunotherapy combined with targeted therapy, immunotherapy combined with chemotherapy, argon-helium cryoablation, and hyperthermic intraperitoneal chemotherapy.

Proficient in chemotherapy, targeted therapy, immunotherapy, endocrine therapy, and other medical treatments for common malignant tumors such as breast cancer, lung cancer, esophageal cancer, gastric cancer, colorectal cancer, liver cancer, head and neck malignant tumors, and pleural mesothelioma; particularly skilled in anti-tumor treatment for elderly patients with malignant tumors.

I. Senior member of the Chinese Society of Immunology

II. Member of the Tumor Hyperthermia Committee of the Chinese Anti-Cancer Association

III. Member of the Molecular Targeted and Immunotherapy Professional Committee of the Hainan Provincial Anti-Cancer Association

IV. Member of the Tumor Chemotherapy Group of the 6th Committee of the Oncology Branch of the Hainan Provincial Medical Association

V. Member of the Second Committee of the Oncology Internal Medicine Physicians Branch of the Hainan Provincial Medical Doctor Association

VI. Member of the Fourth Committee of the Breast Cancer Professional Committee of the Hainan Provincial Anti-Cancer Association

VII. Member of the Hepatobiliary and Pancreatic Minimally Invasive Treatment Professional Committee of the Hainan Provincial Anti-Cancer Association

VIII. Standing Committee Member of the First Committee of the Melanoma Professional Committee of the Hainan Provincial Anti-Cancer Association

IX. Member of the First Professional Committee of Neuroendocrine Tumors of the Hainan Provincial Anti-Cancer Association

X. Member of the Bone and Soft Tissue Tumor Specialty Committee of the Hainan Provincial Cancer Prevention and Treatment Association

XI. Standing Committee Member of the Tumor Rehabilitation and Wellness Specialty Committee of the Hainan Provincial Anti-Cancer Association

XII. Member of the Cancer Pain Integrated Treatment Professional Committee of the Hainan Provincial Anti-Cancer Association

Safe and effective treatment for elderly patients with malignant tumors.

I. Clinical Analysis of Chemotherapy-Related Anemia in Elderly Patients with Malignant Tumors after Surgery. Chinese Journal of Cancer, 2015, (37), (04), 290-292. First Author.

II. The impact of EGFＲ-TKI targeted therapy on tumor markers and survival in elderly patients with advanced lung cancer. Chinese Journal of Geriatrics, 2021, 41(03), 501-503. First author.

III. Incidence and influencing factors of bone marrow suppression in elderly patients with colorectal cancer after chemotherapy. Chinese Journal of Geriatrics, 2021, 41(20), 4391-4394. First author.

IV. Factors contributing to liver failure during targeted therapy in patients with hepatocellular carcinoma. Chinese Journal of Medical Practitioners, 2022, 24(4), 622-625. First author.

V. Efficacy of Thymus Pentapeptide Combined with Qingfei Huazhuo Decoction in the Treatment of Malignant Tumors Complicated with Lung Infection and Its Impact on PCT, CRP, and T Lymphocyte Subset Levels. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2018, (27), (18), 1958-1960. First Author.

VI. The relationship between hepatitis B virus infection and non-Hodgkin lymphoma in some areas of Fuxin. Chinese Journal of Clinical Research, 2014, (27), (11), 1349-1351. First author.

VII. Clinical study on the treatment of malignant ascites caused by gastric cancer with compound sophora flavescens injection combined with intraperitoneal infusion of lobaplatin. Liaoning Journal of Traditional Chinese Medicine. 2021, 48(02), 124-125. First author.

VIII. Erythropoietin for Advanced Cancer Patients Undergoing Chemotherapy. Chinese Medicine Guide Journal, 2017, (15), (25), 160. First Author.